Stock AGEN AGENUS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Agenus Inc.

Equities

AGEN

US00847G8042

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
10.86 USD +3.43% Intraday chart for Agenus Inc. +3.53% -34.41%
May. 16 Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer CI
May. 07 Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT

Evolution of the average Target Price on Agenus Inc.

Price target over the last 5 years

History of analyst recommendation changes

9ab4614d366008a6038a3a.VQRsaatyJaa5MaIdZ6YOx6n_Q-2ckss5F_yDCaW-Gmc.YDM_OsEEQPb3QchrKc9vpdOGB6bZw_9SLpfsefDdSB8ATgEf80MRwN5b6w~1a1b4801963e6df749fdeb49ba59e901

Analyst Recommendations on Agenus Inc.

B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating MT
B. Riley Lowers Agenus' Price Target to $6 From $8, Maintains Buy Rating MT
Baird Initiates Agenus at Outperform With $8 Price Target MT
HC Wainwright Assumes Agenus at Buy With $8 Price Target MT
EF Hutton Starts Agenus With Buy Rating, Sets Price Target at $8.30 MT
EF Hutton Initiates Agenus With Buy Rating, Price Target is $8.3 MT
SMBC Nikko Starts Agenus at Outperform With $5 Price Target MT
B. Riley Lowers Agenus' Price Target to $8 from $11, Keeps Buy Rating MT
HC Wainwright Adjusts Agenus' Price Target to $14 from $12, Reiterates Buy Rating MT
HC Wainwright Starts Agenus at Buy With $12 Price Target MT
Agenus : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 Trial MT
AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to Drive Stock Price Performance; Keeps Buy Rating MT
AGENUS : B. Riley Raises Agenus' PT to $11 from $8, Notes Value Accretive Catalysts; Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.86 USD
Average target price
44.25 USD
Spread / Average Target
+307.46%
High Price Target
60 USD
Spread / Highest target
+452.49%
Low Price Target
35 USD
Spread / Lowest Target
+222.28%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Agenus Inc.

B. Riley
Baird
HC Wainwright
EF Hutton
SMBC Nikko

Ratings for Agenus Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AGEN Stock
  4. Consensus Agenus Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW